The 5 Most Shorted Dow Stocks
As of the most recently reported period, short sellers still favored Exxon, Pfizer and Microsoft above all other Dow stocks.
As of the most recently reported period, short sellers still favored Exxon, Pfizer and Microsoft above all other Dow stocks.
As of the most recently reported period, short sellers still favored Exxon, Pfizer and Microsoft above all other Dow stocks.
As of the most recently reported period, short sellers favored Exxon, Pfizer and Microsoft above all other Dow stocks.
As of the most recently reported period, short sellers favored Exxon, Pfizer and Microsoft above all other Dow stocks. The overall trend of shrinking short interest continued.
BioNTech and Pfizer stocks each made a handy gain on Monday after the companies announced the beginning of human trials for a COVID-19 vaccine.
Merck and Pfizer reported their most recent quarterly results before the opening bell Tuesday. Although markets appear to be recovering, investors were not thrilled about this quarter for these two pharmaceutical giants.
Pharmaceutical giants Merck and Pfizer are expected to report their most recent quarterly results before the opening bell Tuesday.
The April 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
As of the most recently reported period, short sellers favored Exxon, Microsoft and Pfizer above all other Dow stocks.
Over one-third of the Dow Jones industrial average components are scheduled to report their latest quarterly reports this week. Here's what to expect.
BioNTech shares shot up on Wednesday after the company announced, in conjunction with Pfizer, that its COVID-19 vaccine program was approved in Germany.
The March 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
As of the most recently reported period, short sellers favored Exxon, Microsoft and Pfizer above all other Dow stocks. It was a period in which short interest in these stocks was shrinking…
Pfizer and BioNTech each saw gains on Thursday after the companies announced additional details regarding their collaboration in the fight against COVID-19.
Until late Monday, Amarin continued to get good news relevant to Vascepa, its treatment for cardiovascular disease. The big news, though, was lurking in Nevada federal district court.